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Abstract
Intracellular levels of zinc have shown a strong inverse correlation to growth and malignancy of
prostate cancer. To date, studies of zinc supplementation in prostate cancer have been equivocal
and have not accounted for bioavailability of zinc. Therefore, we hypothesized that direct intratumoral injection of zinc could impact prostate cancer growth. In this study, we evaluated the
cytotoxic properties of the pH neutral salt zinc acetate on the prostate cancer cell lines PC3,
DU145 and LNCaP. Zinc acetate killed prostate cancer cell lines in vitro, independent of androgen
sensitivity, in a dose-dependent manner in a range between 200 and 600 μM. Cell death occurred
rapidly with 50% cell death by six hours and maximal cell death by 18 hours. We next established
a xenograft model of prostate cancer and tested an experimental treatment protocol of direct
intra-tumoral injection of zinc acetate. We found that zinc treatments halted the growth of the
prostate cancer tumors and substantially extended the survival of the animals, whilst causing no
detectable cytoxicity to other tissues. Thus, our studies form a solid proof-of-concept that direct
intra-tumoral injection of zinc acetate could be a safe and effective treatment strategy for prostate
cancer.

Background
In the United States alone, 200,000 men are diagnosed
with prostate cancer each year and one out of six men will
be diagnosed in their lifetime. As many as 30,000 men die
from this disease each year in the US, making prostate
cancer the second biggest cancer killer of men, behind
lung cancer[1]. However, several distinct features of the
prostate gland open up unique opportunities for treatment of this cancer. First, the prostate is a nonessential

organ, often making complete surgical resection a viable
option, albeit one with permanent unpleasant side effects
for the patient. Secondly, during early phases of the disease, the malignant prostatic lesions tend to remain focal
and restrictively localized to the prostate gland itself. This,
combined with the anatomic accessibility of the prostate
gland, makes direct intra-tumoral injection of carcinotoxic and carcinostatic agents a real possibility for effective
and relatively noninvasive treatment[2]. In this study,
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based in part on promising in vitro results from our laboratory, we explore the effectiveness of direct intra-tumoral
injection of zinc acetate into malignant prostatic tumors.
Zinc is the most abundant trace element in the human
body and is vital for the function of many enzymes and
proteins in all cells and tissues of the body. There are over
300 zinc-dependent enzymes and zinc is required for the
formation of the zinc-finger motif that is an essential component for nearly all transcription factors and many other
proteins that bind nucleic acids[3]. It has long been
known that chronic insufficient dietary zinc leads to many
debilitating developmental defects, but emerging evidence now links marginally deficient zinc consumption,
such as that which affects more than 10% of the US population, to such diseases as anorexia nervosa, Ahlzeimer's
Disease, and cancer. Several studies have found that men
who consume below the USDA recommended daily
allowance (RDA) of 11 mg/day are at increased risk of
developing prostate cancer[4]. Conversely, other studies
have shown that high-dose supplements of zinc can
increase the risk of prostate cancer[5]. Thus, the role of
dietary zinc in the predisposition to prostate cancer
requires further study.
The relationship between dietary zinc and prostate cancer
likely stems from the vital role that zinc plays in prostate
function. Zinc is known to accumulate in the prostate,
and this gland typically harbors the highest concentration
of zinc in the body[6]. This is because the secretory cells of
the prostate require high levels of zinc to inhibit the
enzyme m-aconitase, which normally functions to oxidize
citrate during the Krebs cycle. Because citrate is a principle
component of seminal fluid, prostate secretory cells do
not complete the oxidation of citrate in the mitochondria
and the zinc-mediated inhibition of m-aconitase is crucial
for the accumulation of citrate in these cells, and thus the
subsequent secretion of citrate into seminal fluid[7]. The
accumulation of zinc in the prostate epithelium is accomplished by the zinc transporter ZIP1, which is highly
expressed in normal prostate tissue[8].
Because zinc is thus antagonistic to the synthesis of ATP in
the cells of the prostate gland, it is not surprising that both
ZIP1 expression and the accumulation of zinc are markedly attenuated in a cancerous prostate [9]. [10]. Indeed,
ZIP1 is considered a prostate tumor suppressor as the
inhibition of its function is requisite for malignant transformation, and prostatic zinc levels have shown an
inverse relationship with tumorigenicity [11]. Thus, the
restoration of zinc levels in prostate cancer cells is a logical
strategy for clinical treatment. Further, zinc has been
shown to be required for mitochondrial apoptogenesis in
prostate cells in vitro [12], and infusions of moderate
doses of zinc reliably lead to apoptosis of prostate cancer
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cell lines [13]. This has led to the hypothesis that clinical
administration of zinc could be an effective chemotherapeutic for prostate cancer. However, studies of zinc dietary
supplementation for cancer prevention have had mixed
results [14,15].
Recently, vascular delivery of zinc was evaluated as a
potential treatment in a mouse model of prostate cancer
[6]. Although an increase in apoptosis was observed in the
prostate cancer xenografts of the mice receiving high doses
of zinc, there was little effect on the overall growth and
aggressiveness of the prostate tumors themselves. Because
ZIP1 function is known to be impaired in prostate cancer
cells, we presume that there was limited homing of zinc to
the prostate cancer xenografts. Thus, we reason that a
localized infusion of zinc, and thus a greater local concentration, could circumvent the reduced ZIP1 activity and
allow greater bioaccumulation of zinc in the diseased
prostate. This is important because intravenous doses of
zinc are limited due to the cellular toxicity of this heavy
metal at super-physiologic concentrations.
In this study, we hypothesize that the direct intra-tumoral
injection of zinc could be a safe and efficacious treatment
for prostate cancer. To our knowledge, this is the first
examination of intra-tumoral zinc delivery as a treatment
strategy for prostate cancer, and we feel that these data
form powerful preliminary evidence indicating that such
a minimally invasive strategy could be efficacious. Furthermore, because of the preferential accumulation of
zinc in prostate tissue, it is conceivable that such a strategy
could be entirely free of the debilitating and dose-limiting
side effects typical of other cancer chemotherapeutics.

Methods
Cell lines
PC3, DU148, LNCaP cells were originally obtained from
ATCC (Rockville, Maryland, USA). Cells were maintained
at 37°C, 5% CO2 and 95% humidity in DMEM (CellGro,
Herndon, Virginia, USA) supplemented with 10% (v/v)
heat inactivated fetal bovine serum (BioWhittaker, Walkersville, Maryland, USA), 2 mM L-glutamine and 100
units/ml penicillin and 1000 ug/ml streptomycin (Invitrogen, Carlsbad, California, USA).
Animals
NOD/SCID mice at 8 weeks of age were purchased from
Charles River Laboratories (Wilmington, Massachusetts,
USA) and were housed at the Saint Louis University comparative medicine facility. Animals were allowed to acclimate for 2 weeks prior to experimentation. The animals
were under the care of a staff veterinarian and managed in
accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals.
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Xenografts
PC3 cells grown to 70% confluence were harvested and
injected in the dorsum of animals subcutaneously. Each
inoculum consisted of 100 μL of cell suspension at a concentration of 107 cells/ml in phosphate-buffered saline.
Tumors were allowed to grow to a size of 300 mm3 prior
to intra-tumoral injection. Tumors were injected with 200
μL of 3 mM zinc acetate solution every 48 hours. Tumors
were measured every 2–3 days with digital calipers. Tumor
volume was determined using the following formula: Volume = Length × Width2.
Zinc Measurements
Zinc was quantified in serum and tissues using the TSQ
fluorophore (Invitrogen, Carlsbad, California, USA). 50
mM TSQ was prepared in 10 mM Tris buffer (ph = 8.0).
TSQ was added to samples and standard zinc solutions to
a final concentration of 10 μM in black round-bottom 96
well plates. Endpoint fluorescence was read on a Spectfluor with excitation wavelength of 360 nm and emission
wavelength of 535 nm. Tissue zinc levels were measured
similarly, after weighing and homogenizing tissue in
water by repeated freeze/thaw cycles.
MTT Assay
Cell viability was determined via MTT assay. Briefly,
media was aspirated from cells grown in 6 well plates and
1 ml of MTT (1 mg/ml) solution was added. After 1 hour
incubation, MTT solution was aspirated and 0.04 N HCL
was added to solubilize the cells and absorbance at 540
nM was measured.

Results
Zinc has been shown to be cytotoxic to a variety of cancer
cell lines [16-18]. In these studies, different formulations
of zinc have been utilized. Unfortunately, in vivo measurements regarding the bio-pharmocokinetics of these different zinc salts are lacking. For this study, we have selected
zinc acetate as it is pH neutral in aqueous solution with
minimal effect on osmalarity, relative to other formulations of zinc. Cytotoxic effects of zinc acetate have not
been reported.
In order to examine the general effectiveness of zinc in
inducing cell death in prostate cancer cells, we selected
three cell lines with distinct properties, representative of
the distinct forms in which prostate cancers emerge. For
example, PC3 and DU145 cells are androgen-independent, while LNCaP cells are androgen-dependent[19]. The
molecular pathways associated with carcinogenesis vary
as well between these cell lines[20] as determined by gene
expression analysis. For example, PSA is upregulated in
LNCaP but not expressed in PC3 or DU145. Using markedly different prostate cancer cell lines allowed us to ana-
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lyze the effect of zinc irrespective of underlying pathways
of transformation.
Induction of apoptosis of prostate cancer cells by zinc
In figure 1, we show that treatment with zinc acetate leads
to widespread cell death within 18 hours in three different
prostate cancer cell lines (figure 1A). Importantly, cell
death is sharply dose-dependent over a broad range from
100–600 μM and the cytotoxicity curves indicate that
300–400 μM zinc acetate, depending on cell line, is effective at inducing cell death in ~80% of the cell population
within just 18 hours (figure 1A). Having established that
zinc acetate has a rapid cytotoxic effect on prostate cancer
cell lines, we next established the time course of cell killing in vitro. Although only data for PC3 cells are shown,
for all three cell lines, 400 μM zinc acetate induced cell
death quite rapidly, with 50% cell death occurring by 6
hours (figure 1B and data not shown). By 24 hours,
greater than 95% of the cells had perished. Interestingly,
zinc dose had minimal effect on the kinetics of cell death,
as doubling the dose to 800 μM zinc only reduced the
EC50 by approximately 90 minutes (figure 1B).

Although maximal cytotoxicity is seen within 24 hours
with doses of 400 μM zinc or higher, we reasoned that
longer incubations with lower doses of zinc might also
have a cytotoxic effect on prostate cancer cells. Thus, we
next evaluated zinc-induced cytotoxicity in PC3 cells at
lower doses and found that, surprisingly, at each dose,
maximum cell death again occurred by 24 hours with little further cell death thereafter (data not shown). However, prolonged exposure to zinc, even at the lowest dose
of 100 μM, has a cytostatic effect: cellular proliferation
halted and the number of cells remained constant over
time (data not shown). Indeed, this cytostatic effect of
prolonged exposure to zinc was observed at all doses
explored in this study.
Effect of Zinc Acetate on PC3 Xenograft Growth
Given these promising in vitro results, we next examined
whether zinc treatments could affect prostate cancer cells
in vivo. To that end, we established a human prostate cancer xenograft model by injecting a bolus of PC3 cells subcutaneously into the dorsal region of SCID mice. To date,
detailed toxicity reports of zinc acetate in mice are lacking.
However, experiments with mice have revealed an LD50
of approximately 50 mg/kg for zinc chloride [21]. Because
the maximal tolerable dose of zinc acetate has not been
established and given that chronic liver changes were
observed at the LD50 dose, we elected to use a dose that
approximated one-eighth of the LD50, 200 μL of 3 mM
zinc acetate. In a pilot study, we observed that a single
dose of zinc acetate had no measurable effect on tumor
growth (data not shown). In addition, because previous
studies have established that zinc is rapidly distributed in
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Figure 1and Toxicity of Zinc Acetate on Prostate Cancer Cell Lines
Kinetics
Kinetics and Toxicity of Zinc Acetate on Prostate Cancer Cell Lines. Prostate cancer cell lines (Panel A: PC3,
DU145, and LNCaP; Panels B and C: PC3) were treated with the indicated concentrations of zinc acetate for either 18 hours
(A) or indicated length of time (B and C). Data represent mean cell viability as assessed by MTT assay (n = 3 independent cell
populations) and error bars represent standard deviation.
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total body water and cleared by renal filtration within 24
hours[22], we elected to administer repeated doses of zinc
acetate in 48 hours intervals in order to establish a chronic
treatment protocol, while limiting untoward zinc bio-toxicity and stress to animals due to the repeated anesthesia
and injection.

sists after the injection schedule is terminated on the fourteenth day (figure 2). Importantly, the growth of
xenografts was unaffected by the anesthesia and injection
procedure per se as vehicle-injected tumors display growth
kinetics indistinguishable from that of non-injected
xenografts.

When the prostate tumor xenografts reached 300 mm3,
treatments were begun: 200 μL of 3 mM zinc acetate by
direct intratumoral injection every 48 hours for a period
of two weeks. We selected this somewhat large tumor size
for both ease of intratumoral injection, and also for
greater accuracy and consistency when using size as an
outcome measure. Figure 2 demonstrates the effect of the
zinc injections on tumor growth and it is immediately
clear that intratumoral injections of zinc have a profound
negative effect on growth of the tumor xenografts. The
injection of zinc dramatically halts the aggressive growth
of PC3 xenografts and, importantly, the growth arrest per-

Bioavailability of zinc following intra-tumoral injection
Because of the promising results of arrested prostate cancer cell growth following zinc injection, we next turned
our attention to the biodistribution of the zinc in this context. We began with simple subcutaneous injections of
zinc acetate in otherwise un-treated SCID mice and found
that single injections of zinc result in a rapid increase in
serum zinc levels as early as 10 minutes after administration (figure 3A). However, serum zinc levels peak in 90
minutes and return to normal physiological levels within
24 hours (figure 3A). We next examined the pharmacokinetics of intra-tumoral injection of zinc acetate into our
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Figureof2Direct Intra-Tumoral Zinc Injection on PC3 Growth
Effect
Effect of Direct Intra-Tumoral Zinc Injection on PC3 Growth. Prostate cancer cell xenografts were placed into SCID
mice and allowed to grow to a size of 300 mm3. Every 48 hours for 14 days, mice were then anesthetized and injected with 200
μL of either saline (black squares) or 3 mM zinc acetate (grey circles). Tumor size was measured at the indicated intervals.
Error bars represent average size for 10 mice and "*" represents significance at p < 0.05 by ANOVA.
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Serum Zinc Levels after Subcutaneous or Intratumoral Zinc Injection. Serum levels were measured at the indicated
times following either a subcutaneous (A) or an intratumoral (B) single 200 μL injection of 3 mM zinc acetate. Data is presented as an average and errors bars indicate the standard deviation of four mice (n = 4).
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prostate cancer xenografts model. The resulting kinetics of
zinc distribution are similar: serum zinc levels rise quite
rapidly after tumor injection, reaching a maximum within
90 minutes, followed by a steady decline to baseline levels
within 24 hours (figure 3B). A significant difference is that
peak serum zinc levels are considerably less when injected
into tumors then subcutaneously indicating either slower
release from tumor tissue or significant uptake into tumor
tissue.
We also sought to examine the homing of zinc to different
tissues, following a single intra-tumoral injection. As
shown in figure 4A, although the liver displayed the greatest concentration of zinc, there is no significant difference
in zinc levels after zinc administration, although we
observed considerable variability between animals. Similarly, there appears to be a reproducible but statistically
insignificant accumulation of zinc within the xenograft
tumors, even after a single administration (figure 4A). We
then extended these observations to conditions of chronic
zinc administration and found that our intratumoral zinc
injection protocol results in a substantial increase in zinc
levels within the tumor xenograft cells, but not in any
brain, heart, kidney, or liver (figure 4B). This confirms our
supposition that intra-tumoral injection allows for a
much higher local concentration of zinc, which in turn
may overcome impaired zinc import and thus, increased
partitioning of therapeutic zinc into the diseased prostate
tissue.

http://www.jeccr.com/content/28/1/84

humane reasons, a scoring system was established to
assess animal welfare and animals not able to meet two
requirements were euthanized. The scoring system consisted of the following: 1. Maintenance of normal weight
(Weight loss > 12%); 2. Normal ambulation; 3. Normal
grooming; 4. Normal feeding. Importantly, the decision
to remove an animal from the protocol due to extreme
tumor burden was made by an animal care technician
unaware of the treatment group of the particular animal at
the time of the decision.
Thus, humane removal of an animal from the protocol
was recorded as a death event, and with these data we
evaluated survival. As seen in figure 5, intra-tumoral injection of zinc acetate significantly extended the lifespan of
animals in this xenograft model of prostate cancer. Dramatically, although the treatment protocol extended for
only two weeks, the enhanced survival of animals in the
zinc treatment group was persistent for several weeks
beyond (figure 5). In the control group, all animals had
succumbed to the debilitating effects of the growing
tumor within eight weeks of the beginning of the treatment protocol. However, in the same time period, 80% of
those treated with zinc acetate injections remained alive
(figure 5). This dramatic result was significant (p = 0.002)
by Kaplan-Meier Survival Analysis and revealed the intratumoral injection can halt the growth of prostate cancer in
vivo with marked in gains in survival.

Discussion
Zinc Biosafety
Over the course of our experiments, we were able to limit
prostate xenograft growth over a period of two weeks.
Even after zinc administration was discontinued, tumor
growth was slower than in control animals (figure 2).
Importantly, at the dosage delivered to the animals, we
did not observe any evidence of biotoxicity during the
treatment protocol and no animal death was recorded.
Further, a blinded pathologist performed a full post-mortum histological analysis of tissues and uncovered no evidence of tissue toxicity in the animals enrolled in the zinc
treatment protocol (data not shown). Liver changes
reported by others at the LD50 level were not seen with
our substantially lower dosage even with the chronic
administration schedule.
Survival of Animals following treatment of prostate cancer
xenografts with zinc
As a final measure of the potential usefulness of zinc as a
component of prostate cancer chemotherapeutics, we
assayed the ability of the intra-tumoral zinc injection protocol to extend the life of animals in our prostate cancer
xenograft model. Because they are growing subcutaneously rather than orthotopically xenograft tumors may
grow to significant size without causing animal death. For

Prostate cancer represents a unique clinical problem with
respect to treatment options. 90% of men will present
with localized disease [23]. For these men, the current
treatment paradigm is prostatectomy or radiotherapy. For
men with advanced disease, androgen therapy offers the
best opportunity for long term survival. However, treatment may be limited by the androgen responsive nature
of the tumor. Given the age at which many men present
with prostate cancer and the slow growing nature of this
cancer, in many cases, the treatment options may have
equivalent morbidity in comparison to the cancer itself.
Hence, less invasive methods of treatment with fewer side
effects would be very advantageous for men presenting
with localized disease.
There is much to suggest that treatment with zinc has real
clinical potential. It is solidly established that reduced
intracellular zinc levels are necessary for maintaining the
malignant phenotype of prostate cancer cells [24] and that
malignancy and tumor aggressiveness are inversely proportional to tumoral zinc levels [25]. Thus, the current
paradigm for zinc in prostate cancer suggests that loss of
intracellular zinc is vital to the transformation of normal
prostate tissue into cancerous prostate tissue, likely due to
the metabolic effects of zinc in the Krebs cycle. That is,
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was also quite rapid indicating that prolonged exposure is
not necessary for zinc effects on prostate cancer cells.
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Figureof5Intra-Tumoral Zinc Injection on Survival
Effect
Effect of Intra-Tumoral Zinc Injection on Survival.
Prostate cancer cell xenografts were placed into SCID mice
and allowed to grow to a size of 200 mm3. Every 48 hours
for 14 days, mice were then anesthetized and injected with
200 μL of either saline or 3 mM zinc acetate. Mice were evaluated by a blinded technician and sacrificed when tumor burden reached predetermined criteria for humane maintenance
and care. Difference in mean survival between treatment and
control groups was significant (p < 0.002) by Kaplan-Meier
Survival Analysis.

because zinc inhibits m-aconitase, loss of zinc allows for
greater energy utilization, supporting the substantially
increased cellular metabolism that is necessary for rapid
proliferation [26].
Because systemic (i.e. intravenous) injection of zinc has
limitations and is poorly targeted to diseased prostate, in
this study we evaluated whether increasing zinc bioavailability through direct injection into tumors would impact
prostate cancer malignancies. Although repeated intratumoral injections may not be a desirable treatment modality for human prostate cancer patients, we have provided
proof of concept that increase of intraprostatic zinc can
effectively moderate prostate tumor growth.

Human physiological serum zinc levels are approximately
70–100 μg/dL. This represents total zinc and not any particular salt form. As such, it is difficult to reconcile levels
with molar doses used in our in vitro studies, but it is clear
that our in vitro doses could not be achieved systemically
in a whole animal without undue toxicity. However, we
hypothesized that, given the rapid nature by which zincmediated cell death occurs in prostate cancer cells, the
local microenvironment could be altered to a level sufficient to impact tumor growth whilst avoiding widespread
toxicity. Thus, in an attempt to maximize the anti-tumor
effect and minimize the biotoxicity, we selected a dose
that was approximately 8-fold less than the LD50 toxic
dose reported for rodents. Based on the fact that we had
no observed tissue biotoxicity, future studies could determine the maximum tolerable dose for direct zinc administration.

Conclusion
Our results showed that despite rapid dissipation of zinc
into total body water there was a local effect of diminishing tumor growth over time. Although our administration
schedule is an impractical method for the treatment of
local disease in humans, our studies have established that
administration of zinc in the tumor microenvironment
can have a potent anti-tumor effect. Direct injection into
tumors did result in increasing tumor tissue zinc levels
and altered growth over time, an effect that persisted long
after zinc injections were ceased. Our data indicate that
methods to increase zinc in the prostate tumor microenvironment could be useful as a way of modulating growth
of localized disease. Given rapid physiological clearance
of zinc, the use of zinc would likely have limited systemic
toxicity. Consequently, injection of biogels or depot formulations of zinc may be an alternative strategy to
increasing intraprostatic zinc resulting in anti-tumor effect
with limited biotoxicity.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
In our in vitro experiments, we have shown that increasing
zinc in the microenvironment to 200–600 μM can cause
rapid prostate cancer cell death. Cell death was independent of the mechanism of molecular carcinogenesis and
independent of androgen sensitivity. Others have
reported that the mechanism of zinc associated prostate
cancer cell death is apoptotic with a shift in Bax/BCL2
ratios[27] and the morphological changes seen in our
studies are consistent with apoptotic cell death. Cell death

MRS, CK and JB contributed equally to the design and
implementation of the study. MRS was responsible for all
statistical analysis. MRS and NHL drafted the manuscript.
CLK and MKH equally contributed to carrying out all in
vitro zinc toxicity studies. CLK performed all of the animal
experimentation. NJ and CLK performed all zinc level
determinations. All authors have read and approved manuscript.

Page 9 of 10
(page number not for citation purposes)

Journal of Experimental & Clinical Cancer Research 2009, 28:84

http://www.jeccr.com/content/28/1/84

Acknowledgements

22.

The authors wish to thank Dr. Craig Lawson for evaluating all of the slides
for the biotoxicity studies.

23.

This work was supported by DOD Grant pc 061410.
24.

References
1.

2.

3.
4.
5.
6.
7.
8.

9.
10.
11.
12.
13.
14.
15.

16.
17.

18.
19.
20.
21.

Kamo K, Sobue T: Cancer statistics digest. Mortality trend of
prostate, breast, uterus, ovary, bladder and "kidney and
other urinary tract" cancer in Japan by birth cohort. Jpn J Clin
Oncol 2004, 34(9):561-563.
Springate CM, Jackson JK, Gleave ME, Burt HM: Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing
paclitaxel or docetaxel in prostate cancer xenograft models.
Cancer Chemother Pharmacol 2005, 56(3):239-247.
Prasad AS: Zinc: the biology and therapeutics of an ion. Ann
Intern Med 1996, 125(2):142-144.
Heshmat MY, Kaul L, Kovi J, Jackson MA, Jackson AG, Jones GW,
Edson M, Enterline JP, Worrell RG, Perry SL: Nutrition and prostate cancer: a case-control study. Prostate 1985, 6(1):7-17.
Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL: Zinc supplement use and risk of prostate cancer. J
Natl Cancer Inst 2003, 95(13):1004-1007.
Feng P, Li TL, Guan ZX, Franklin RB, Costello LC: Effect of zinc on
prostatic tumorigenicity in nude mice. Ann N Y Acad Sci 2003,
1010:316-320.
Costello LC, Franklin RB, Liu Y, Kennedy MC: Zinc causes a shift
toward citrate at equilibrium of the m-aconitase reaction of
prostate mitochondria. J Inorg Biochem 2000, 78(2):161-165.
Franklin RB, Ma J, Zou J, Guan Z, Kukoyi BI, Feng P, Costello LC:
Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells. J Inorg Biochem 2003, 96(2–
3):435-442.
Desouki MM, Geradts J, Milon B, Franklin RB, Costello LC: hZip2
and hZip3 zinc transporters are down regulated in human
prostate adenocarcinomatous glands. Mol Cancer 2007, 6:37.
Habib FK, Mason MK, Smith PH, Stitch SR: Cancer of the prostate:
early diagnosis by zinc and hormone analysis? Br J Cancer 1979,
39(6):700-704.
Costello LC, Franklin RB: Novel role of zinc in the regulation of
prostate citrate metabolism and its implications in prostate
cancer. Prostate 1998, 35(4):285-296.
Costello LC, Franklin RB, Feng P: Mitochondrial function, zinc,
and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 2005, 5(3):143-153.
Liang JY, Liu YY, Zou J, Franklin RB, Costello LC, Feng P: Inhibitory
effect of zinc on human prostatic carcinoma cell growth.
Prostate 1999, 40(3):200-207.
Costello LC, Feng P, Milon B, Tan M, Franklin RB: Role of zinc in
the pathogenesis and treatment of prostate cancer: critical
issues to resolve. Prostate Cancer Prostatic Dis 2004, 7(2):111-117.
Gallus S, Foschi R, Negri E, Talamini R, Franceschi S, Montella M, Ramazzotti V, Tavani A, Dal Maso L, La Vecchia C: Dietary zinc and
prostate cancer risk: a case-control study from Italy. Eur Urol
2007, 52(4):1052-1056.
Ronowska A, Gul-Hinc S, Bielarczyk H, Pawelczyk T, Szutowicz A:
Effects of zinc on SN56 cholinergic neuroblastoma cells. J
Neurochem 2007, 103(3):972-983.
Dubi N, Gheber L, Fishman D, Sekler I, Hershfinkel M: Extracellular
zinc and zinc-citrate, acting through a putative zinc-sensing
receptor, regulate growth and survival of prostate cancer
cells. Carcinogenesis 2008, 29(9):1692-1700.
Franklin RB, Costello LC: Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys 2007,
463(2):211-217.
Sobel RE, Sadar MD: Cell lines used in prostate cancer
research: a compendium of old and new lines – part 1. J Urol
2005, 173(2):342-359.
Yang M, Loda M, Sytkowski AJ: Identification of genes expressed
differentially by LNCaP or PC-3 prostate cancer cell lines.
Cancer Res 1998, 58(16):3732-3735.
Bay BH, Wang MC, Yip GW: Effect of intraperitoneal administration of zinc on C57/6J mouse liver – a light microscopic
study. Okajimas Folia Anat Jpn 1998, 74(6):279-291.

25.
26.
27.

Krebs NE, Hambidge KM: Zinc metabolism and homeostasis:
the application of tracer techniques to human zinc physiology. Biometals 2001, 14(3–4):397-412.
Dahm P, Yeung LL, Chang SS, Cookson MS: A critical review of
clinical practice guidelines for the management of clinically
localized prostate cancer. J Urol 2008, 180(2):451-459.
Costello LC, Franklin RB: The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer 2006, 5:17.
Zaichick V, Sviridova TV, Zaichick SV: Zinc in the human prostate
gland: normal, hyperplastic and cancerous. Int Urol Nephrol
1997, 29(5):565-574.
Singh KK, Desouki MM, Franklin RB, Costello LC: Mitochondrial
aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol Cancer 2006, 5:14.
Feng P, Li T, Guan Z, Franklin RB, Costello LC: The involvement
of Bax in zinc-induced mitochondrial apoptogenesis in malignant prostate cells. Mol Cancer 2008, 7:25.

Publish with Bio Med Central and every
scientist can read your work free of charge
"BioMed Central will be the most significant development for
disseminating the results of biomedical researc h in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours — you keep the copyright

BioMedcentral

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

Page 10 of 10
(page number not for citation purposes)

